New Research Outlines Future for Developing Oral Medicines That Work More Efficiently
University of Minnesota and The Dow Chemical Company tackle one of the biggest challenges in health care
18-Apr-2018 11:05 AM EDT
Newswise — MINNEAPOLIS/ST. PAUL (04/18/2018) — Researchers at the University of Minnesota and The Dow Chemical Company have joined forces to tackle one of the biggest challenges in health care—how to get life-saving medicines to work faster and better with fewer side effects.
In a new review article published today on the cover of the American Chemical Society’s journal Bioconjugate Chemistry, the researchers examined dozens of publications on the topic and then outlined the future for improvements in developing oral medicines that work more efficiently.
One of the challenges for pharmaceutical companies when developing oral medications to treat a wide variety of diseases, from hepatitis C to HIV, is to ensure that the body will fully absorb the drug molecules. Many therapeutic structures do not easily dissolve on the molecular level in the patient’s body, which means they are less effective. In those cases, the dose must be increased for patients, which may increase side effects.
Drug companies add substances, called excipients, to help the medicines dissolve in the stomach and intestinal fluid, but there have been few improvements implemented in recent years to this decades-old technology. The study examines the excipients used for several existing medicines and suggests improvements.
“In this article, we survey the latest techniques, materials, and formulations for developing molecularly customized excipients that could greatly improve the future of how oral medications are developed,” said Theresa Reineke, a University of Minnesota chemistry professor and study co-author. “This information will be helpful in future research in both industry and academia that could help millions of people worldwide.”
The researchers specifically focused on the well-established manufacturing pharmaceutical technique, called spray drying, which can be used in drug and tablet formulations as an effective strategy to improve effectiveness of medicines that usually don’t dissolve well in liquids. The control methods they examined could be easily scaled up from the milligram to the metric ton.
“Over the past decade, we have found that advancements in the spray-drying technique has helped researchers worldwide prepare heat-stable vaccines to combat measles, influenza, and a host of other diseases,” said Jeff Ting, a former University of Minnesota chemical engineering Ph.D. student and first author of the study who is currently a postdoctoral researcher at the University of Chicago. “With more research we hope there will be more successes in the future.”
The researchers say that the future will depend on the continuation of critical partnerships between industry and academia, like the one between Dow and the University of Minnesota.
“This study will be a strong resource for looking at what has already been done in this field, and, more importantly, what exciting things are coming on the horizon,” said William “Trey” Porter III, an associate research scientist in The Dow Chemical Company’s Larkin Laboratory and a co-author of the study. “We could have never done this study without the University, and the University could not have done the study without Dow. We need collaboration with academics to help us dive deeper into this research, but industry can help keep the team grounded in the real challenges facing developers of new medicines.”
The study is the most recent result of a long-standing collaboration between The Dow Chemical Company and the University of Minnesota for research partnerships to develop new chemical solutions, improve research facilities, and train the next generation of scientists.
This new study was funded primarily by The Dow Chemical Company with additional support from a National Science Foundation Graduate Research Fellowship and a University of Minnesota Doctoral Dissertation Fellowship.
In addition to Reineke, Ting and Porter, the other authors of the article are Jodi Mecca, a senior research specialist at The Dow Chemical Company, and Frank Bates, a chemical engineering and materials science professor at the University of Minnesota.
To read the full article, entitled “Advances in Polymer Design for Enhancing Oral Drug Solubility and Delivery,” visit the Bioconjugate Chemistry website.